- Cantharidin
| (-)-p-Bromotetramisole OxalateALP inhibitor, potent and non-specific |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 99.34%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Description | (-)-p-Bromotetramisole Oxalate is a potent and non-specific inhibitor of alkaline phosphatase. | |||||
| Targets | alkaline phosphatase | |||||
| IC50 | ||||||
| Cell experiment [1]: | |
Cell lines | neurosecretory PC12 cells |
Preparation method | The solubility of this compound in DMSO is >18.7mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 0.3 mM |
Applications | In neurosecretory PC12 cells, (-)-p-Bromotetramisole Oxalate significantly enhanced 5 μM ionomycin-stimulated [3H] NA release from PC12 cells. (-)-p-Bromotetramisole Oxalate alone only slightly stimulated [3H] NA release. |
| Animal experiment [2]: | |
Animal models | thyroparathyroidectomized Sprague-Dawley rats |
Dosage form | systemic infusion at 0.8 ml/min of 10 mM (-)-p-Bromotetramisole Oxalate |
Application | In thyroparathyroidectomized Sprague-Dawley rats, (-)-p-Bromotetramisole Oxalate significantly increased fractional excretion of phosphate (FEPi) from 4.7%±0.9% to 13.4%±3.1%. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Kitamura T, Murayama T, Nomura Y. Enhancement of Ca2+-induced noradrenaline release by vanadate in PC12 cells: possible involvement of tyrosine phosphorylation. Brain Res, 2000, 854(1-2): 165-171. [2]. Onsgard-Meyer M, McCoy AL, Knox FG. Effect of bromotetramisole on renal phosphate excretion. Proc Soc Exp Biol Med, 1996, 213(2): 193-195. | |
(-)-p-Bromotetramisole Oxalate Dilution Calculator
calculate
(-)-p-Bromotetramisole Oxalate Molarity Calculator
calculate
| Cas No. | 62284-79-1 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | N/A | ||
| Canonical SMILES | BrC(C=C1)=CC=C1[C@H]2N=C3SCCN3C2.OC(C(O)=O)=O | ||
| Formula | C13H13BrN2O4S | M.Wt | 373.22 |
| Solubility | ≥18.65mg/mL in DMSO | Storage | Desiccate at -20°C |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
(-)-p-Bromotetramisole Oxalate (L-(-)-p-Bromotetramisole Oxalate, L-p-Bromotetramisole Oxalate, (-)-4-Bromotetramisole Oxalate) is a potent and non-specific inhibitor of alkaline phosphatase and is also an inhibitor of protein tyrosine phosphatases [1] [2].
Alkaline phosphatase is a hydrolase enzyme that removes phosphate groups from nucleotides, proteins and alkaloids. Protein tyrosine phosphatase is an enzyme that removes phosphate groups from phosphorylated tyrosine residues on target proteins.
(-)-p-Bromotetramisole Oxalate is an inhibitor of alkaline phosphatase and protein tyrosine phosphatases. In various rat tissues, (-)-p-Bromotetramisole Oxalate (0.1 μM) completely inhibited non-specific alkaline phosphatase [1]. In rat zona glomerulosa, (-)-p-Bromotetramisole Oxalate (100 μM) blocked the inhibition of Na+ pump (Na+, K+-ATPase) induced by angiotensin II. The result suggested that inhibition of the Na+ pump induced by angiotensin II might be mediated by a tyrosine phosphatase [2]. In neurosecretory PC12 cells, (-)-p-Bromotetramisole Oxalate (0.3 mM) increased ionomycin-stimulated noradrenaline (NA) release, which suggested that tyrosine phosphorylation regulated Ca2+-stimulated NA release [3].
In Sprague-Dawley rats, (-)-p-Bromotetramisole Oxalate (10 μM) significantly increased fractional excretion of phosphate (FEPi) from 4.7% to 13.4% [4].
References:[1]. Borgers M, Thoné F. The inhibition of alkaline phosphatase by L-p-bromotetramisole. Histochemistry, 1975, 44(3): 277-280.[2]. Yingst DR, Davis J, Schiebinger R. Inhibitors of tyrosine phosphatases block angiotensin II inhibition of Na(+) pump. Eur J Pharmacol, 2000, 406(1): 49-52.[3]. Kitamura T, Murayama T, Nomura Y. Enhancement of Ca2+-induced noradrenaline release by vanadate in PC12 cells: possible involvement of tyrosine phosphorylation. Brain Res, 2000, 854(1-2): 165-171.[4]. Onsgard-Meyer M, McCoy AL, Knox FG. Effect of bromotetramisole on renal phosphate excretion. Proc Soc Exp Biol Med, 1996, 213(2): 193-195.
